Skip to main content
SpringerLink
Log in

Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors “A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome”

  • Letter to the Editors
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

The Original Article was published on 11 April 2016

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hansen E, Sahasrabudhe D, Sievert L (2016) A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother. doi:10.1007/s00262-016-1835-4

    Google Scholar 

  2. Martin-Liberal J, Furness AJ, Joshi K et al (2015) Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 64:765–767

    Article  PubMed  Google Scholar 

  3. International MHC and Autoimmunity Genetics Network, Rioux JD et al (2009) Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci USA 106:18680–18685

    Article  Google Scholar 

  4. Dubin K, Callahan MK, Ren B et al (2016) Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 7:10391

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Melanoma Unit, Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK

    Lavinia Spain & James Larkin

  2. Department of Medical Oncology, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Pg Vall d’Hebron, 119-129, 08035, Barcelona, Spain

    Juan Martin-Liberal

Authors
  1. Lavinia Spain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Larkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan Martin-Liberal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juan Martin-Liberal.

Ethics declarations

Conflict of interest

James Larkin is a non-remunerated consultant for Novartis, Pfizer, BMS, MSD and Roche/Genentech and receives institutional research support from Pfizer, BMS, Novartis, and MSD. Lavinia Spain and Juan Martin-Liberal have no relevant disclosures.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Spain, L., Larkin, J. & Martin-Liberal, J. Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors “A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome”. Cancer Immunol Immunother 65, 769–770 (2016). https://doi.org/10.1007/s00262-016-1845-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-016-1845-2

Keywords

Search

Navigation